ID   Reh
AC   CVCL_1650
SY   REH
DR   BTO; BTO:0001163
DR   CLO; CLO_0008781
DR   CLO; CLO_0008782
DR   CLDB; cl4132
DR   AddexBio; C0003031/4985
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-8286
DR   BCRJ; 0321
DR   BioSample; SAMN03471040
DR   BioSample; SAMN03473380
DR   BioSample; SAMN10988185
DR   CCLE; REH_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCRID; 3131C0001000700131
DR   Cell_Model_Passport; SIDM00447
DR   ChEMBL-Cells; CHEMBL3308823
DR   ChEMBL-Targets; CHEMBL2366320
DR   CLS; 300320/p630_REH
DR   Cosmic; 798668
DR   Cosmic; 801720
DR   Cosmic; 909696
DR   Cosmic; 919149
DR   Cosmic; 991551
DR   Cosmic; 994183
DR   Cosmic; 996287
DR   Cosmic; 998706
DR   Cosmic; 999751
DR   Cosmic; 1012114
DR   Cosmic; 1037725
DR   Cosmic; 1067440
DR   Cosmic; 1118468
DR   Cosmic; 1130244
DR   Cosmic; 1191700
DR   Cosmic; 1483360
DR   Cosmic; 1524815
DR   Cosmic; 2491075
DR   Cosmic; 2523595
DR   Cosmic; 2649233
DR   Cosmic-CLP; 909696
DR   DepMap; ACH-000960
DR   DSMZ; ACC-22
DR   GDSC; 909696
DR   GEO; GSM236802
DR   GEO; GSM236838
DR   GEO; GSM482492
DR   GEO; GSM499514
DR   GEO; GSM499538
DR   GEO; GSM499727
DR   GEO; GSM499733
DR   GEO; GSM887530
DR   GEO; GSM888612
DR   GEO; GSM931330
DR   GEO; GSM931331
DR   GEO; GSM1195448
DR   GEO; GSM1374847
DR   GEO; GSM1670369
DR   GEO; GSM2373798
DR   GEO; GSM2373799
DR   LiGeA; CCLE_618
DR   LINCS_LDP; LCL-1039
DR   Lonza; 58
DR   PharmacoDB; REH_1299_2019
DR   Wikidata; Q29958043
RX   DOI=10.1007/BF00204739;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=197411;
RX   PubMed=2140233;
RX   PubMed=7630190;
RX   PubMed=7888679;
RX   PubMed=8704231;
RX   PubMed=8847894;
RX   PubMed=9067587;
RX   PubMed=9108419;
RX   PubMed=8704231;
RX   PubMed=9510473;
RX   PubMed=9680106;
RX   PubMed=9823951;
RX   PubMed=10490826;
RX   PubMed=14504097;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=16523483;
RX   PubMed=20164919;
RX   PubMed=21552520;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=27922598;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   http://www.proteinatlas.org/learn/cellines
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=699
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 34.7 hours (PubMed=8847894); 30 hours (PubMed=25984343); ~50-70 hours (DSMZ).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: ETV6-RUNX1 (TEL-AML1) gene fusion (PubMed=8704231; PubMed=9067587; PubMed=15843827).
CC   Omics: Array-based CGH.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=21.18%; Native American=0.09%; East Asian, North=1.57%; East Asian, South=2%; South Asian=1.52%; European, North=15.6%; European, South=58.04% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11,12 (AddexBio; ATCC; PubMed=25877200)
ST   CSF1PO: 12,13 (CLS; Cosmic-CLP; DSMZ)
ST   D13S317: 11,13 (AddexBio; ATCC; PubMed=25877200)
ST   D13S317: 11,12,13 (CLS)
ST   D13S317: 11,14 (Cosmic-CLP)
ST   D13S317: 10,11,14 (DSMZ)
ST   D16S539: 9 (AddexBio; ATCC; PubMed=25877200)
ST   D16S539: 9,10,12,13 (CLS)
ST   D16S539: 9,13 (Cosmic-CLP; DSMZ)
ST   D18S51: 10,11,14 (CLS)
ST   D18S51: 10,14 (PubMed=25877200)
ST   D21S11: 28,29,30,31 (CLS)
ST   D21S11: 28,30 (PubMed=25877200)
ST   D3S1358: 18
ST   D5S818: 11,13 (AddexBio; ATCC; PubMed=25877200)
ST   D5S818: 11,12,13 (CLS)
ST   D5S818: 11,12 (Cosmic-CLP; DSMZ)
ST   D7S820: 9,12 (AddexBio; ATCC; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   D7S820: 9,10,12,13 (CLS)
ST   D8S1179: 13,14,16,17 (CLS)
ST   D8S1179: 13,15 (PubMed=25877200)
ST   FGA: 22,23,24 (CLS)
ST   FGA: 22,23 (PubMed=25877200)
ST   Penta D: 9,12 (CLS)
ST   Penta D: 9,11 (PubMed=25877200)
ST   Penta E: 10,11 (CLS)
ST   Penta E: 7,11 (PubMed=25877200)
ST   TH01: 7 (AddexBio; ATCC; CLS; PubMed=25877200)
ST   TH01: 7,9 (Cosmic-CLP; DSMZ)
ST   TPOX: 8
ST   vWA: 14,15 (AddexBio; ATCC; Cosmic-CLP; PubMed=25877200)
ST   vWA: 14,15,16 (CLS; DSMZ)
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 32
//
RX   DOI=10.1007/BF00204739;
RA   Bertoglio J., Guibout C., Dore J.-F., Rosenfeld C.;
RT   "Further characterization of a non-T, non-B acute lymphoblastic
RT   leukaemia cell line (Reh). Reactivity with human sera cytotoxic for
RT   leukaemia cells.";
RL   Cancer Immunol. Immunother. 4:193-196(1978).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=197411; DOI=10.1038/267841a0;
RA   Rosenfeld C., Goutner A., Choquet C., Venuat A.M., Kayibanda B.,
RA   Pico J.L., Greaves M.F.;
RT   "Phenotypic characterisation of a unique non-T, non-B acute
RT   lymphoblastic leukaemia cell line.";
RL   Nature 267:841-843(1977).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=7630190;
RA   Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608;
RA   Zhou M., Yeager A.M., Smith S.D., Findley H.W.;
RT   "Overexpression of the MDM2 gene by childhood acute lymphoblastic
RT   leukemia cells expressing the wild-type p53 gene.";
RL   Blood 85:1608-1614(1995).
//
RX   PubMed=8704231; DOI=10.1182/blood.V88.3.785.785;
RA   Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y.,
RA   Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D.;
RT   "TEL-AML1 translocations with TEL and CDKN2 inactivation in acute
RT   lymphoblastic leukemia cell lines.";
RL   Blood 88:785-794(1996).
//
RX   PubMed=8847894;
RA   Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K.,
RA   Nakamura H., Amakawa R., Ohno H.;
RT   "Sensitivity to dexamethasone and absence of bcl-2 protein in
RT   Burkitt's lymphoma cell line (Black93) derived from a patient with
RT   acute tumor lysis syndrome: comparative study with other BL and non-BL
RT   lines.";
RL   Leukemia 10:1592-1603(1996).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=9108419; DOI=10.1182/blood.V89.8.2986;
RA   Findley H.W., Gu L., Yeager A.M., Zhou M.;
RT   "Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with
RT   p53 status and sensitivity to apoptosis in childhood acute
RT   lymphoblastic leukemia.";
RL   Blood 89:2986-2993(1997).
//
RX   PubMed=8704231; DOI=10.1182/blood.V88.3.785.785;
RA   Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y.,
RA   Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D.;
RT   "TEL-AML1 translocations with TEL and CDKN2 inactivation in acute
RT   lymphoblastic leukemia cell lines.";
RL   Blood 88:785-794(1996).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=9823951; DOI=10.1038/sj.leu.2401198;
RA   Zhou M., Gu L., Yeager A.M., Findley H.W.;
RT   "Sensitivity to Fas-mediated apoptosis in pediatric acute
RT   lymphoblastic leukemia is associated with a mutant p53 phenotype and
RT   absence of Bcl-2 expression.";
RL   Leukemia 12:1756-1763(1998).
//
RX   PubMed=10490826; DOI=10.1038/sj.onc.1202874;
RA   Fu X., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.;
RT   "EB-1, a tyrosine kinase signal transduction gene, is
RT   transcriptionally activated in the t(1;19) subset of pre-B ALL, which
RT   express oncoprotein E2a-Pbx1.";
RL   Oncogene 18:4920-4929(1999).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=16523483; DOI=10.1002/gcc.20317;
RA   Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H.,
RA   Dexter T., Ashworth A., Kearney L.;
RT   "Array CGH of fusion gene-positive leukemia-derived cell lines reveals
RT   cryptic regions of genomic gain and loss.";
RL   Genes Chromosomes Cancer 45:554-564(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.,
RA   Tucker M., Kornhauser J., Ren J., MacNeill J., Gygi S.P., Druker B.J.,
RA   Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27922598; DOI=10.1038/leu.2016.371;
RA   Charmsaz S., Al-Ejeh F., Yeadon T.M., Miller K.J., Smith F.M.,
RA   Stringer B.W., Moore A.S., Lee F.-T., Cooper L.T., Stylianou C.,
RA   Yarranton G.T., Woronicz J., Scott A.M., Lackmann M., Boyd A.W.;
RT   "EphA3 as a target for antibody immunotherapy in acute lymphoblastic
RT   leukemia.";
RL   Leukemia 31:1779-1787(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//